Effect of potassium magnesium citrate and vitamin B-6 prophylaxis for recurrent and multiple calcium oxalate and phosphate urolithiasis

Korean Journal of Urology

Volumn 55, Issue 6, 2014, Pages 411-416

  Krishna Reddy, S ^a   Shaik, Ahammad Basha ^a   Bokkisam, Suneel ^a  

^a NARAYANA MEDICAL COLLEGE   (India)

Author keywords

Calcium oxalate; Potassium magnesium citrate; Pyridoxine; Urolithiasis

Indexed keywords

CITRATE POTASSIUM; MAGNESIUM CITRATE; PLACEBO; PYRIDOXINE; UNCLASSIFIED DRUG; URIC ACID; URIKIND KM6;

ADULT; ARTICLE; CALCIUM OXALATE STONE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; FEMALE; FLUID INTAKE; FOLLOW UP; HUMAN; HYPERURICOSURIA; HYPOCITRATURIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STONE FORMATION; URINARY EXCRETION; URINE PH; URINE VOLUME; UROGENITAL SYSTEM PARAMETERS; UROLITHIASIS;

EID: 84902588669     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2014.55.6.411     Document Type: Article

References (29)

1. Ramello A, Vitale C, Marangella M. Epidemiology of nephrolithiasis. J Nephrol 2000;13 Suppl 3:S45-50.
2. Turney BW, Reynard JM, Noble JG, Keoghane SR. Trends in urological stone disease. BJU Int 2012;109:1082-7.
3. Ljunghall S, Danielson BG. A prospective study of renal stone recurrences. Br J Urol 1984;56:122-4.
4. Shetty PS. Nutrition transition in India. Public Health Nutr 2002;5(1A):175-82.
5. Taylor EN, Curhan GC. Fructose consumption and the risk of kidney stones. Kidney Int 2008;73:207-12.
6. Meschi T, Maggiore U, Fiaccadori E, Schianchi T, Bosi S, Adorni G, et al. The effect of fruits and vegetables on urinary stone risk factors. Kidney Int 2004;66:2402-10.
7. Taylor EN, Curhan GC. Oxalate intake and the risk for nephrolithiasis. J Am Soc Nephrol 2007;18:2198-204.
8. Koyuncu HH, Yencilek F, Eryildirim B, Sarica K. Family history in stone disease: how important is it for the onset of the disease and the incidence of recurrence? Urol Res 2010;38:105-9.
9. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. Family history and risk of kidney stones. J Am Soc Nephrol 1997;8:1568-73.
10. D'Angelo A, Calo L, Cantaro S, Giannini S. Calciotropic hormones and nephrolithiasis. Miner Electrolyte Metab 1997;23:269-72.
11. Paliouras C, Trampikaki E, Alirasis P, Aperis G. Pathophysiology of nephrolithiasis. Nephrol Rev 2012;4:e14.
12. Johri N, Cooper B, Robertson W, Choong S, Rickards D, Unwin R. An update and practical guide to renal stone management. Nephron Clin Pract 2010;116:c159-71.
13. Hamm LL, Hering-Smith KS. Pathophysiology of hypocitraturic nephrolithiasis. Endocrinol Metab Clin North Am 2002;31: 885-93.
14. Domrongkitchaiporn S, Stitchantrakul W, Kochakarn W. Causes of hypocitraturia in recurrent calcium stone formers: focusing on urinary potassium excretion. Am J Kidney Dis 2006;48:546-54.
15. Welch BJ, Graybeal D, Moe OW, Maalouf NM, Sakhaee K. Biochemical and stone-risk profiles with topiramate treatment. Am J Kidney Dis 2006;48:555-63.
16. Melnick JZ, Preisig PA, Haynes S, Pak CY, Sakhaee K, Alpern RJ. Converting enzyme inhibition causes hypocitraturia independent of acidosis or hypokalemia. Kidney Int 1998;54: 1670-4.
17. Amanzadeh J, Gitomer WL, Zerwekh JE, Preisig PA, Moe OW, Pak CY, et al. Effect of high protein diet on stone-forming propensity and bone loss in rats. Kidney Int 2003;64:2142-9.
18. Marangella M, Vitale C, Manganaro M, Cosseddu D, Martini C, Petrarulo M, et al. Renal handling of citrate in chronic renal insufficiency. Nephron 1991;57:439-43.
19. Weinstein DA, Somers MJ, Wolfsdorf JI. Decreased urinary citrate excretion in type 1a glycogen storage disease. J Pediatr 2001;138:378-82.
20. Pak CY. Physicochemical basis for formation of renal stones of calcium phosphate origin: calculation of the degree of saturation of urine with respect to brushite. J Clin Invest 1969;48:1914-22.
21. Pak CY, Sakhaee K, Peterson RD, Poindexter JR, Frawley WH. Biochemical profile of idiopathic uric acid nephrolithiasis. Kidney Int 2001;60:757-61.
22. Pak CY. Citrate and renal calculi: an update. Miner Electrolyte Metab 1994;20:371-7.
23. Lee SY, Moon YT. Clinical significance of hypocitraturia in patients with nephrolithiasis. Korean J Urol 2006;47:631-4.
24. Kok DJ, Papapoulos SE, Bijvoet OL. Excessive crystal agglomeration with low citrate excretion in recurrent stone-formers. Lancet 1986;1:1056-8.
25. Tiselius HG. The effect of pH on the urinary inhibition of calcium oxalate crystal growth. Br J Urol 1981;53:470-4.
26. Hosking DH, Erickson SB, Van den Berg CJ, Wilson DM, Smith LH. The stone clinic effect in patients with idiopathic calcium urolithiasis. J Urol 1983;130:1115-8.
27. Pak CY, Peterson R. Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate. Arch Intern Med 1986;146:863-7.
28. Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 1997;158:2069-73.
29. Jaipakdee S, Prasongwatana V, Premgamone A, Reungjui S, Tosukhowong P, Tungsanga K, et al. The effects of potassium and magnesium supplementations on urinary risk factors of renal stone patients. J Med Assoc Thai 2004;87:255-63.